Summary
Edwards Lifesciences Corporation (EW) reported strong performance in its 2009 10-K filing, highlighting significant growth driven by its Heart Valve Therapy segment, particularly the SAPIEN transcatheter heart valve and advanced surgical valves. The company demonstrated robust revenue growth of 6.8% year-over-year to $1.32 billion, with international markets contributing a substantial 58% of total sales. The company's commitment to research and development is evident, with a 13.3% increase in R&D spending to $175.5 million, focused on expanding its transcatheter valve technology and critical care monitoring systems. Despite global economic headwinds, Edwards Lifesciences maintained healthy gross profit margins around 70% and managed its selling, general, and administrative expenses effectively. The company also repurchased stock and maintained a strong liquidity position with a $500 million revolving credit facility. Overall, the filing paints a picture of a leading medical technology company with a strong product pipeline, effective execution, and a clear strategy for future growth in the cardiovascular disease treatment market.
Financial Highlights
49 data points| Revenue | $1.32B |
| Cost of Revenue | $399.10M |
| Gross Profit | $922.30M |
| R&D Expenses | $175.50M |
| SG&A Expenses | $508.80M |
| Interest Expense | $2.70M |
| Net Income | $229.10M |
| EPS (Basic) | $0.34 |
| EPS (Diluted) | $0.33 |
| Shares Outstanding (Basic) | 675.00M |
| Shares Outstanding (Diluted) | 705.00M |
Key Highlights
- 1Revenue grew by 6.8% to $1.32 billion in 2009, driven by strong performance in Heart Valve Therapy and international markets.
- 2Heart Valve Therapy segment sales increased by 17.7% to $714.9 million, fueled by the Edwards SAPIEN transcatheter heart valve and new surgical valve launches.
- 3Research and Development expenses increased by 26% to $175.5 million, reflecting continued investment in innovation, particularly in transcatheter valve technologies.
- 4Gross profit margin remained strong at 69.8%, indicating efficient operations and pricing power.
- 5International sales represented 58% of total net sales, demonstrating the company's global reach and diversified revenue streams.
- 6The company maintained a healthy liquidity position, with $334.1 million in cash and cash equivalents and $500 million available under its revolving credit facility.
- 7The company repurchased $95.5 million of its common stock in 2009, signaling confidence in its financial health and value.